Papers/PMID:40324865
Efficacy and safety of empagliflozin in acute heart failure: a systematic review and meta-analysis.
Future cardiology2025The record
2 findings · 1 compound · 2 endpoints
What it reported
How to read these marksWhat moved
2 findings
empagliflozin — decreases all-cause mortality
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.Finding“Empagliflozin reduced all-cause mortality (OR: 0.47, 95% CI: 0.29-0.78, p = 0.004) and cardiovascular death (OR: 0.56, 95% CI: 0.38-0.82, p = 0.003) compared to placebo.”
Quoted verbatim from Efficacy and safety of empagliflozin in acute heart failure: a systematic review and meta-analysis.. - Study
- meta-analysis
- Population
- Adults with acute heart failure; pooled randomised placebo-controlled trials
Effect 0.47 odds ratio, 95% CI 0.29 to 0.78
Efficacy and safety of empagliflozin in acute heart failure: a systematic review and meta-analysis.2025PMID:40324865Permalink
empagliflozin — decreases cardiovascular mortality
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.Findingreplicated ×1“Empagliflozin reduced all-cause mortality (OR: 0.47, 95% CI: 0.29-0.78, p = 0.004) and cardiovascular death (OR: 0.56, 95% CI: 0.38-0.82, p = 0.003) compared to placebo.”
Quoted verbatim from Efficacy and safety of empagliflozin in acute heart failure: a systematic review and meta-analysis.. - Study
- meta-analysis
- Population
- Adults with acute heart failure; pooled randomised placebo-controlled trials
Effect 0.56 odds ratio, 95% CI 0.38 to 0.82
Efficacy and safety of empagliflozin in acute heart failure: a systematic review and meta-analysis.2025PMID:40324865Permalink